Anti-atherosclerotic therapy based on botanicals

Recent Patents on Cardiovascular Drug Discovery

Volumn 8, Issue 1, 2013, Pages 56-66

  Orekhov, Alexander N ^a,b   Sobenin, Igor A ^a,b,c   Korneev, Nikolay V ^d   Kirichenko, Tatyana V ^a,b   Myasoedova, Veronika A ^a,b   Melnichenko, Alexandra A ^a,b   Balcells, Mercedes ^e,f   Edelman, Elazer R ^e,g   Bobryshev, Yuri V ^a,b,h  

^a Institute for Atherosclerosis Research   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d Ministry of Defense of the Russian Federation   (Russian Federation)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Anti atherosclerotic therapy; Atherosclerosis; Botanicals; Clinical studies; Intima media thickness; Natural products; Ultrasonography of carotid arteries

Indexed keywords

ALLICOR; CARDIOVASCULAR AGENT; CHOLESTEROL; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTI ATHEROSCLEROTIC THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENICITY; B SCAN; BOTANY; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DRUG THERAPY; GARLIC; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALPHA-TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GARLIC; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878757895     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/18722083113079990008     Document Type: Article

References (77)

1. Palozza P, Catalano A, Simone RE, Mele MC, Cittadini A. Effect of lycopene and tomato products on cholesterol metabolism. Ann Nutr Metab 2012; 61: 126-34.
2. Giordano P, Scicchitano P, Locorotondo M, Mandurino C, Ricci G, Carbonara S, et al. Carotenoids and cardiovascular risk. Curr Pharm Des 2012; 18: 5577-89.
3. Sposito AR, Aguiar Filho GB, Aarão AR, Sousa FT, Bertolami MC. Statins in acute coronary syndromes. Arq Bras Cardiol 2011; 97: 350-6.
4. Wong, N.C. W., Tucker, J. E.L., Hansen, H.C., Chiacchia, F.S., McCaffrey, D. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases. US8242130 (2012).
5. Fan, C.T., Lai, C.S., Lin, M.J. Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same. US8202995 (2012).
6. Hansen, H.C., Chopade, S.P., Citineni, J.R., Short, R.P., Yiannikouros, G.P. Methods of preparing quinazolinone derivatives. US8114995 (2012).
7. Wong, N.C. W., Tucker, J. E.L., Hansen, H.C., Chiacchia, F.S., McCaffrey, D. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases. US7846915 (2010).
8. Kumar, A. Composition and manufacturing processes of a toxicity free botanical drug for curative treatment of chronic diseases. WO092712 (2011).
9. Tripp, M. L., Babish, J. G., Bland, J.S., Hall, Amy J., Konda, V., Pacioretty, L. M. Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes. US20070281045 (2007).
10. Leonard, A., Saltzman, D., Mueller, M. Method and use of coldpressed botanic seed oils for lowering blood pressure and LDL cholesterol. US20080260645 (2008).
11. Bhagat, U. Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof. WO051591 (2012).
12. Niazi, S.K. Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides, and sugar and preventing or treating cardiovascular diseases. US20040253327 (2004).
13. Managoli, N.B. Herbal composition for treatment of hyperlipidemia and the inhibition of myocardial infarction. US8067043 (2011)
14. Rangel, O., Angel, J. Angina pectoris and ischemic heart disease and synergistic phytoceutical composition for same. US8231913 (2012).
15. Montecucco F, Quercioli A, Mirabelli-Badenier M, Viviani GL, Mach F. Statins in the treatment of acute ischemic stroke. Curr Pharm Biotechnol 2012; 13: 68-76.
16. Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS. Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Curr Pharm Des 2009; 15: 3094-107.
17. Sipahi I, Tuzcu EM. Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: Insight from intravascular ultrasonography trials. Am J Cardiovasc Drugs 2008; 8: 365-71.
18. Riboldi P, Gerosa M, Meroni PL. Statins and autoimmune diseases. Lupus 2005; 14: 765-8.
19. Toth PP. New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin. Curr Atheroscler Rep 2005; 7: 335-43.
20. Ganesh SK, Nass CM, Blumenthal RS. Anti-atherosclerotic effects of statins: Lessons from prevention trials. J Cardiovasc Risk 2003; 10(3): 155-9.
21. Orekhov AN, Tertov VV. In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. Lipids 1997; 32: 1055-60.
22. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM. Direct antiatherosclerosis- related effects of garlic. Ann Med 1995; 27: 63-5.
23. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
24. Tertov VV, Orekhov AN, Nikitina NA, Perova NV, Lyakishev AA, Serebrennikov SG, et al. Peritoneal macrophages: a model for detecting atherogenic potential in patients' blood serum. Ann Med. 1989; 21: 455-459.
25. Adams DO. Macrophages. Methods Enzymol 1979; 58: 494-505.
26. Hara A, Radin NS. Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem. 1978; 90: 420-6.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
28. Simon A, Giral P, Levenson J. Extracoronary atherosclerotic plaque at multiple sites and total coronary calcification deposit in asymptomatic men. Association with coronary risk profile. Circulation 1995; 92:1414-21.
29. Mitchell J.R., Schwartz C.J. Relationship between arterial disease at different sites. Br Med J 1962; 1: 1293-301.
30. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. A case-control study. Circulation 1990; 82: 1230-42.
31. Geroulakos G, O'Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 1994; 15: 781-5.
32. Geroulakos G, O'Gorman D, Nicolaides A, Sheridan D, Elkeles R, Shaper AG. Carotid intima-media thickness: correlation with the British Regional Heart Study risk score. J Intern Med 1994; 235: 431-3.
33. Crouse JR 3rd, Craven TE, Hagaman AP, Bond MG. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 1995; 92: 1141-7.
34. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14: 177-92.
35. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9.
36. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87: 1156-65.
37. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146: 483-94.
38. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432-7.
39. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
40. Tertov VV, Orekhov AN, Ryong LH, Smirnov VN. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cells. Tissue Cell 1988; 20: 849-54.
41. Orekhov AN, Tertov VV, Kudryashov SA, Smirnov VN. Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res 1990; 66: 311-20.
42. Harenberg J, Giese C, Zimmermann R. Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia. Atherosclerosis. 1988; 74: 247-9.
43. Lau B, Lam F, Wang-Chen R. Effect of odor-modified garlic preparation on blood lipids. Nutr Res 1987; 7: 139-49.
44. Neil HA, Silagy CA, Lancaster T, Hodgeman J, Vos K, Moore JW, et al. Garlic powder in the treatment of moderate hyperlipidaemia: A controlled trial and meta-analysis. J R Coll Physicians Lond 1996; 30: 329-34.
45. Silagy C, Neil A. Garlic as a lipid lowering agent - a meta-analysis. J R Coll Physicians Lond 1994; 28: 39-45.
46. Koscielny J, Klüssendorf D, Latza R, Schmitt R, Radtke H, Siegel G, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis 1999; 144: 237-49.
47. Campbell JH, Efendy JL, Smith NJ, Campbell GR. Molecular basis by which garlic suppresses atherosclerosis. J Nutr 2001; 131: 1006S-1009S.
48. Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
49. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
50. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.
51. Hodis HN. Reversibility of atherosclerosis-evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. J Cardiovasc Pharmacol 1995; 25 (Suppl 4): S25-S31.
52. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intimamedia thickness measured by ultrasound. Circulation 1993; 88: 20-8.
53. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin- Hemphill L, Hodis HN et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-76.
54. Zanchetti A, Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
55. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993; 153: 1065-73.
56. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Twenty-year dynamics of serum cholesterol levels in the middle-aged population of eastern Finland. Ann Intern Med 1996; 125: 713-22.
57. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993; 119: 599-605.
58. Steiner M, Khan AH, Holbert D, Lin RI. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr 1996; 64: 866-70.
59. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds: human and animal studies. J Nutr 2001; 131: 989S-993S.
60. Chazov EI, Tertov VV, Orekhov AN, Lyakishev AA, Perova NV, Kurdanov KA et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986; 2: 595-8.
61. Tertov VV, Orekhov AN, Martsenyuk ON, Perova NV, Smirnov VN. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol 1989; 50: 337-47.
62. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Jaakkola O, Solakivi T, et al. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest 1992; 67: 665-75.
63. Tertov VV, Sobenin IA, Orekhov AN. Characterization of desialylated low-density lipoproteins which cause intracellular lipid accumulation. Int J Tissue React. 1992; 14: 155-62.
64. Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IYu, Martsenyuk ON, Lyakishev AA, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988; 62: 421-9.
65. Orekhov AN, Tertov VV, Kabakov AE, Adamova IYu, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler Thromb. 1991; 11: 316-26.
66. Kacharava AG, Tertov VV, Orekhov AN. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med. 1993; 25: 551-5.
67. Block E. The chemistry of garlic and onions. Sci Am 1985; 252: 114-9.
68. Iberl B, Winkler G, Müller B, Knobloch K. Quantitative determination of allicin and alliin from garlic by HPLC. Planta Med 1990; 56: 320-6.
69. Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. Intake of garlic and its bioactive components. J Nutr 2001; 131: 955S-962S.
70. Slevin M, Ahmed N, Wang Q, McDowell G, Badimon L. Unique vascular protective properties of natural products: supplements or future main-line drugs with significant anti-atherosclerotic potential? Vasc Cell 2012; 4: 9.
71. Aviram, M., Dornfeld, L. Methods of using pomegranate extracts for causing regression in lesions due to arteriosclerosis in humans. US8221806 (2012).
72. Belcaro, G., Burki, C., Ferrari, V. Combination of proanthocyanidins and centella asiatica for the treatment of atherosclerosis. US20120164244 (2012).
73. Davidson MH, Maki KC, Dicklin MR, Feinstein SB, Witchger M, Bell M, McGuire DK, Provost JC, Liker H, Aviram M. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol 2009; 104: 936-42.
74. Orekhov, A.N., Sobenin, I.A., Kirichenko, T.V., Myasoedova, V.A., Melnichenko, A.A., Orekhova, V.A. Method of prevention and treatment of atherosclerosis. RU02455016 (2012).
75. Orekhov, A.N. Agent Carinat for prophylaxis of cardiovascular and oncological diseases. RU02129874 (1999).
76. Bespalov, V.G., Barash, N.Ju., Ivanova, O.A., Krzhivitskij, P.I., Semiglazov, V.F., Aleksandrov, V.A., Orekhov, A.N., Sobenin, I.A. Method for treating mastopathy. RU02226400 (2004).
77. Bespalov, V.G., Aleksandrov, V.A., Shcherbakov, A.M., Kalinovskij, V.P., Novik, V.I., Chepik, O.F., Orekhov, A.N., Sobenin, I.A. Method for treating the cases of chronic atrophic gastritis. RU02219940 (2003).